دورية أكاديمية
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
| العنوان: | Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction |
|---|---|
| المؤلفون: | Lima-Posada, Ixchel, Stephan, Yohan, Soulié, Matthieu, Bonnard, Benjamin, Nicol, Lionel, Kolkhof, Peter, Jaisser, Frederic, Mulder, Paul, Palacios-Ramirez, Roberto |
| سنة النشر: | 2023 |
| المجموعة: | UVaDOC - Repositorio Documental de la Universidad de Valladolid |
| مصطلحات موضوعية: | diabetes, heart failure, mineralocorticoid receptor antagonist, diastolic dysfunction, finerenone |
| الوصف: | Producción Científica ; The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Antagonizing the overactivation of the MR with MR antagonists (MRA) is a therapeutic option, but their use in patients with CKD is limited due to the associated risk of hyperkalemia. Finerenone is a non-steroidal MRA associated with an improved benefit-risk profile in comparison to steroidal MRAs. In this study, we decided to test whether finerenone improves renal and cardiac function in male hypertensive and diabetic ZSF1 rats as an established preclinical HFpEF model. Finerenone was administered at 10 mg/kg/day for 12 weeks. Cardiac function/hemodynamics were assessed in vivo. ZSF1 rats showed classical signs of CKD with increased BUN, UACR, hypertrophy, and fibrosis of the kidney together with characteristic signs of HFpEF including cardiac fibrosis, diastolic dysfunction, and decreased cardiac perfusion. Finerenone treatment did not impact kidney function but reduced renal hypertrophy and cardiac fibrosis. Interestingly, finerenone ameliorated diastolic dysfunction and cardiac perfusion in ZSF1 rats. In summary, we show for the first time that non-steroidal MR antagonism by finerenone attenuates cardiac diastolic dysfunction and improves cardiac perfusion in a preclinical HFpEF model. These cardiac benefits were found to be largely independent of renal benefits. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1422-0067 |
| العلاقة: | https://www.mdpi.com/1422-0067/24/3/2536Test; https://doi.org/10.3390/ijms24032536Test; Int J Mol Sci. 2023 Jan 28;24(3).; https://uvadoc.uva.es/handle/10324/65924Test; 2536; International Journal of Molecular Sciences; 24 |
| DOI: | 10.3390/ijms24032536 |
| الإتاحة: | https://doi.org/10.3390/ijms24032536Test https://uvadoc.uva.es/handle/10324/65924Test |
| حقوق: | Attribution-NonCommercial-NoDerivatives 4.0 Internacional ; info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.CA716C8 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14220067 |
|---|---|
| DOI: | 10.3390/ijms24032536 |